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PSP94, an upstream signaling mediator of prostasin
found highly elevated in ovarian cancer
J-x Ma1,2,6, B-x Yan*,1,3,6, J Zhang3,4, B-H Jiang5, Y Guo1, H Riedel1, MD Mueller1, SC Remick1 and JJ Yu1

Ovarian cancer is a leading cause of cancer death as diagnosis is frequently delayed to an advanced stage. Effective biomarkers
and screening strategies for early detection are urgently needed. In the current study, we identify PSP94 as a key upstream factor
in mediating prostasin (a protein previously reported to be overexpressed in ovarian cancer) signaling that regulates prostasin
expression and action in ovarian cancer cells. PSP94 is overexpressed in ovarian cancer cell lines and patients, and is
significantly correlated with prostasin levels. Signaling pathway analysis demonstrated that both PSP94 and prostasin, as
potential upstream regulators of the Lin28b/Let-7 pathway, regulate Lin28b and its downstream partner Let-7 in ovarian cancer
cells. Expression of PSP94 and prostasin show a strong correlation with the expression levels of Lin28b/Let-7 in ovarian cancer
patients. Thus, PSP94/prostasin axis appears to be linked to the Lin28b/Let-7 loop, a well-known signaling mechanism in
oncogenesis in general that is also altered in ovarian cancer. The findings suggest that PSP94 and PSP94/prostasin axis are key
factors and potential therapeutic targets or early biomarkers for ovarian cancer.
Cell Death and Disease (2014) 5, e1407; doi:10.1038/cddis.2014.374; published online 4 September 2014

Epithelial ovarian cancer is the most lethal gynecologic cancer
and the fourth leading cause of death among women
in developed countries. If diagnosed at stage I with the
malignancy confined to the ovary, the 5-year survival rates
can reach up to 94%. However, survival rates sharply decline
to 28% for advanced stages at presentation.1 Insufficient
biomarker(s) and the lack of an effective screening strategy
for early detection result in 480% of patients presenting with
advanced disease at the time of diagnosis. Serum marker
CA125 (cancer antigen 125) is clinically used in ovarian
cancer screening, but it lacks the sensitivity and specificity to
function independently in a test.2 A sensitive biomarker for
accurate early detection of ovarian cancer is urgently needed.
Prostasin (protease serine 8 or PRSS8) is a trypsin-like
serine peptidase expressed in epithelial cells and is found as a
cell surface bound or secreted protein. Prostasin is altered in
ovarian, prostate, breast and gastric cancers3–6 and has been
proposed to inhibit cancer cell proliferation and invasion upon
activation.7 In particular, prostasin is overexpressed in
ovarian cancer and may serve as a potential biomarker for
early detection of ovarian cancer independently or in
combination with CA125.4,8,9
Prostatic secretory protein 94 (PSP94) also termed microseminoprotein beta (MSMB) is the second most abundant
protein in the semen of healthy men and is found in a
variety of human tissues.10–12 The cellular levels of PSP94
gradually decreases with the progression of prostate cancer,
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suggesting that PSP94 may represent a promising target for
cancer treatment and a potential biomarker for early detection
of prostate cancer.13 In addition, genome-wide association
studies and functional analysis of underlying MSMB gene
correlate with polymorphism of the gene promoter region,
resulting in altered MSMB expression with prostate cancer
risk.14–17
MicroRNAs (miRNAs) regulate gene expression at posttranscriptional level in diversely biological functions such as
cell proliferation, differentiation and apoptosis.18,19 The Let-7
family of miRNAs consists of more than 10 sequenceconserved members with similar functions across diverse
species from worms to humans.20 Deregulation of Let-7 has
been linked to many types of cancer and other diseases.20,21
An RNA-binding protein termed Lin28b was recently identified
as a direct upstream inhibitor of Let-7 family signaling22,23 with
important functions in embryonic stem cells and embryonal
carcinoma cells.24–27 Balanced signaling of Lin28b to Let-7 is
critical; imbalance is linked to various diseases.28
Our recent studies demonstrated important roles and
functional similarity of prostasin and PSP94 in ovarian cancer
chemoresistance.29,30 In the current study, we report that
prostasin expression is regulated by PSP94 and shares all
examined downstream targets with PSP94 in ovarian cancer
cells. PSP94 and prostasin are both overexpressed in strong
correlation with Lin28b/Let-7 expression levels in tissues
of ovarian cancer patients. As a result, PSP94 and the
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PSP94/prostasin axis may represent promising markers for
early detection of ovarian cancer as well as potential
therapeutic targets. This role may be extended to other types
of cancers where either one or both components are altered.
Results
PSP94 regulates prostasin expression in ovarian cancer
cells. PSP94 and prostasin both play important roles in
chemoresistance and share similarities in their actions.29,30
To investigate their possible relationship, we examined
PSP94 expression in prostasin overexpressing cells
(O432-RP-pro-O) and prostasin level in PSP94 overexpressing cells (O432-RP-PSP-O). PSP94 expression was found
unchanged in O432-RP-pro-O when compared to control
cells (Figure 1, lane 3, top band), whereas prostasin level
was found increased in O432-RP-PSP-O cells when
compared to control cells O432-RP-C (Figure 1, lane 2, top
band). These findings are consistent with a role of PSP94 as
an upstream regulator for inducing prostasin expression, but
not vice versa. We extended this observation to a different
ovarian cancer cell line where, similarly, prostasin expression
increased upon PSP94 overexpression (Supplementary
Figure 1). We did not examine PSP94 expression since we
were unable to produce prostasin overexpression, possibly
due to the strong repression function of prostasin in ovarian
cancer cells.30
Prostasin is a downstream mediator of PSP94 in a
shared signaling pathway. We previously showed that
prostasin regulates downstream signaling of the CASP/
PAK2-p34 and MLCK/actin, JNK/c-Jun pathways.30 PSP94
may share these pathways with prostasin as an upstream
mediator. We examined expression levels of various genes
in CASP/PAK2-p34 and MLCK/actin, JNK/c-Jun pathways in
PSP94 overexpressed cells O432-RP-PSP-O. All respective

Figure 1 PSP94 regulates prostasin expression in ovarian cancer cells.
Prostasin and PSP94 protein levels are shown in immunoblots with specific
antibodies in prostasin overexpressed cells O432-RP-pro-O and PSP94 overexpressed cells O432-RP-PSP-O, respectively. Prostasin levels were increased in
both cell models, but PSP94 level was increased only in O432-RP-PSP-O cells with
no change in O432-RP-pro-O cells. O432-RP-C was used as a pCI-neo vector
transfected control cell line
Cell Death and Disease

genes were found to be altered in O432-RP-PSP-O cells
when compared to the control O432-RP-C (Figure 2a), and
showed the same pattern as in prostasin overexpressed
cells (O432-RP-pro-O when compared to the control).30 Our
findings suggest shared signaling mechanisms between
PSP94 and prostasin in CASP/PAK2-p34 and MLCK/actin,
JNK/c-Jun pathways. PSP94 has been shown to regulate the
Lin28/Let-7 loop in ovarian cancer cells.29 To investigate
whether prostasin participates in this mechanism together
with PSP94, we examined Lin28b and Let-7 expression
levels in prostasin overexpressed cells O432-RP-pro-O.
Lin28b level was increased, whereas Let-7 miRNA level
decreased in O432-RP-pro-O cells compared to the control
(Figures 2b and c). Based on our observations, PSP94
appears to function as an upstream mediator of prostasin
and both proteins share all tested downstream targets.
PSP94 regulates prostasin expression, but prostasin does
not appear to affect PSP94 level.
Prostasin and PSP94 have similar roles in chemoresistance
in ovarian cancer29,30 and share downstream targets. Our
data suggest a role for prostasin as a key downstream
target of PSP94 in the development of chemoresistance. To
investigate this hypothesis, we studied O432-RP-PSP-O-pro-D
cells obtained by prostasin-siRNA transfection of O432-RPPSP-O cells (Figure 2d). Both cell lines were treated with
paclitaxel and cell survival was evaluated. As shown in
Figure 2e, the survival of O432-RP-PSP-O-pro-D cells
increased in a dose-dependent manner that indicates greater
resistance to paclitaxel treatment when compared to
O432-RP-PSP-O cells. Knockdown prostasin in O432-RPPSP-O cells appeared to interfere with PSP94 action in
chemoresistance by disconnecting PSP94 from its downstream targets. These data demonstrate that PSP94 is
dependent on prostasin function in the development of
chemoresistance in our experimental model.
PSP94 or the PSP94/prostasin axis is overexpressed in
ovarian cancer cell lines and ovarian cancer patients.
Prostasin is overexpressed in ovarian cancer patients and
several ovarian cancer cell lines4 and PSP94 show a
comparable expression pattern. When we compared
PSP94 protein levels in normal and several ovarian cancer
cell lines, we found high or modest levels of PSP94
expression in all cancer cell lines but not detectable in
normal ovarian cells (Figure 3a). We also quantified PSP94
and prostasin mRNA expression in ovarian cancer tissues.
As shown in Figure 3b, PSP94 mRNA levels are significantly
higher (about four-fold, on average) in tumor tissues of
ovarian cancer patients (at all stages) than in normal
specimens. We also compared mRNA levels in early and
late stages of the disease (stages 1 and 2 were defined as
early stage, versus stages 3, 4 and 5 as late stage). We
observed that PSP94 levels are four to five-fold higher in
early stage samples and slightly elevated above control level
in the late stages. A similar pattern of prostasin expression
was also observed in these samples (Supplementary
Figure 2).
Correlation analysis of PSP94 and prostasin expression
showed significant overlap in ovarian cancer tissues
(Figure 3c). Among 13 matched samples from ovarian cancer
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Figure 2 Prostasin is a downstream mediator of PSP94 in a shared signaling pathway. (a) CASP/PAK2-p34 signaling and further downstream JNK/c-Jun and MLCK/actin
signaling are regulated by PSP94. Expression levels of CASPs, PAK2-p34, JNK, c-Jun, MLCK and actin were examined in PSP94 overexpressed O432-RP-PSP-O cells,
which show the same pattern as prostasin overexpressed cells O432-RP-pro-O. Overexpression of prostasin in O432-RP-pro-O cells upregulates CASP/PAK2-p34 and
further downstream JNK/c-Jun and MLCK/actin signaling molecules (lanes 1, 2 and 3) as previously reported,30 indicating that PSP94 and prostasin share the same
downstream targets. (b and c) Prostasin regulates Lin28b/Let-7 loop in ovarian cancer cells. Expression levels of Lin28b and Let-7 microRNA were examined in prostasin
overexpressed cells (O432-RP-pro-O) and the same expression pattern is seen as in PSP94 overexpressed O432-RP-PSP-O cells. Upregulation of Lin28b by overexpression
of PSP94 (O432-RP-PSP-O; lanes 1, 2 and 4) is consistent with our previous report,29 indicating that PSP94 and prostasin share the same downstream targets. (d) ProstasinsiRNA knockdown. Prostasin protein levels are decreased in O432-RP-PSP-O-pro-D knockdown cells compared to O432-RP-PSP-O (mock transfection control) or O432-RPPSP-O-CS (siRNA transfection control). (e) Prostasin-siRNA knockdown in O432-RP-PSP-O cells appeared to interfere with PSP94 action in chemoresistance. Cells were
plated at 10–20% confluence, treated with paclitaxel at different concentrations for 24 h, and then cultured in normal medium for 7–10 days. Cell survival was evaluated.
Relative survival rates of each cell line are shown

patients (tumor tissue and normal ovary tissue from the same
patient) 11 were seen PSP94 expression increased in tumors
compared to normal tissue (B85%; a Ct value 436
considered as positive expression and vice versa; Figure 3d).
PSP94 protein is secreted in various human tissues
including breast and ovaries.12 To evaluate whether PSP94
could serve as a serum biomarker for early detection of
ovarian cancer, we examined PSP94 protein level in the blood
of normal and ovarian cancer patients. In ovarian cancer

patients (mixed stages), PSP94 levels were 35.7±21.7 ng/ml,
which is significantly higher compared to normal controls
(14.6±12.7 ng/ml; Table 1; Po0.001), confirming that PSP94
is overexpressed in ovarian cancer patients.
PSP94 and prostasin regulate the Lin28/Let-7 loop in
ovarian cancer cells and show correlation with Lin28/
Let-7 expression in cancer patients. Expression of Lin28b
and Let-7 is altered in ovarian cancer.31,32 Our previous
Cell Death and Disease
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Figure 3 PSP94 expression levels are elevated in ovarian cancer cells and tumor tissues. (a) PSP94 expression levels by immunobloting with specific antibodies in human
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studies and current investigation demonstrate that both
PSP94 and prostasin regulate Lin28b/Let-7 expression in
ovarian cancer cells O432-RP29 (Figure 2). Consequently,
the PSP94/prostasin axis may act as an upstream mediator
of the Lin28b/Let-7 loop, altering its expression in ovarian
cancer. We further examined the expression levels of Lin28b
and Let-7 in ovarian cancer tissues by qPCR. As shown in
Figure 4, PSP94 and prostasin showed strong positive
correlation with Lin28b (R ¼ 0.33 and 0.19, respectively), but
negative correlation with Let-7 expression in ovarian cancer
tissues (R ¼  0.26 and  0.27, respectively). These findings suggest a close functional relationship between the
PSP94/prostasin axis and the Lin28b/Let-7 loop in the
development of ovarian cancer.

Discussion
Despite dramatic advances in recent decades in understanding basic cancer mechanisms, ovarian cancer is still a
deadly disease with a five-year survival rate of o50%.33 In
particular, the lack of effective biomarkers for early screening
results in 480% of patients presenting with advanced disease
at the time of diagnosis. In this study, we show that PSP94 is
overexpressed in ovarian cancer patients and cell lines and
functions as an upstream mediator of prostasin. Since PSP94
expression is particularly elevated in early-stage patients
(stages1 and 2), and only somewhat in late-stage patients
Cell Death and Disease

(stages 3 and 4), when compared to normal controls, PSP94
is a possible biomarker for early detection of ovarian cancer.
Other studies report that prostasin is overexpressed in
ovarian cancer and in combination with CA125 provides high
sensitivity (92%) and specificity (94%) to identify cancer
patients, but low sensitivity when used as an individual
marker.4 We propose PSP94 as a more advantageous
biomarker for earlier detection of ovarian cancer, compared
to prostasin. PSP94 is a secreted protein,10 whereas
prostasin is a secreted and membrane protein (glycosylphosphatidylinositol-anchored5), with functional differences
between the two proteins.10,30 Prostasin appears to be
implicated in a much wider spectrum of physiological and
pathophysiological conditions than PSP94 and has important
roles in epidermal barrier function, skin phenotype, embryonic
viability and blood pressure.34–38 In contrast, known functions
of PSP94 are relatively narrow in prostate cancer development and ovarian cancer chemoresistance. Although PSP94
is a promising biomarker for ovarian cancer detection and
treatment, further studies are needed. Large patient samples
are required to determine sensitivity and specificity and
functional studies are necessary to investigate PSP94 (and
its peptide derivative PCK3145) as potential therapeutic
targets.
Our findings show that PSP94 is an upstream mediator of
prostasin in ovarian cancer. PSP94 and prostasin are overexpressed in ovarian cancer patients, and PSP94/prostasin
signaling may play an essential role in ovarian cancer
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development. PSP94 and prostasin levels are both decreased
in prostate cancer; this is consistent with our preliminary
findings that PSP94 regulates prostasin expression in
prostate cancer cells and likely serves as an upstream
signaling mediator of prostasin in prostate cancer development. We expect that PSP94/prostasin signaling may be
important in oncogenesis in general, not just limited to ovarian
cancer (Figure 5), and plays an important role in ovarian
cancer chemoresistance.29,30 Notably, PSP94/prostasin signaling appears to have an opposite role in ovarian cancer
compared to prostate cancer, as PSP94 and prostasin are
overexpressed in ovarian cancer,4 while their expression
levels are decreased in prostate cancer.3,13 Prostasin
expression is also altered in breast and gastric cancers5,6
and it may be meaningful to investigate the corresponding
PSP94 expression in those cancers.
In our study, PSP94 is an upstream signaling mediator of
prostasin in ovarian cancer cells, and both share all
investigated downstream targets; however, prostasin may
have other upstream regulators and downstream signals that
are independent of PSP94 (Figure 5). This is suggested by
some functional differences that we observed between
PSP94 and prostasin in ovarian cancer cells. For example,
recombinant PSP94 or PSP94-derived peptide PCK3145

Table 1 PSP94 levels in the blood of normal and ovarian cancer patients

Mean S.D. Range n
(ng/ml)
Cancer
patients
Normal

Age

P

35.7

21.7

0–78

19 31–69 0.0007

14.6

12.7

0–61

28 29–78

6
4

Mixed
stages

represses some ovarian cancer cells, in contrast to recombinant prostasin. Overexpression of prostasin in ovarian cancer
cells greatly induces cell death and represses cell survival,
whereas overexpression of PSP94 in ovarian cancer cells
does not significantly affect cell death.29,30 Thus, further
studies on differences between these two genes in ovarian
cancer are needed to comprehensively understand their role
in oncogenesis.
Lin28b was recently identified as an RNA-binding protein
and direct upstream mediator and inhibitor of Let-7 family.22,23
Alteration of Let-7 or Lin28b has been linked to many types of
cancers and other diseases, and the Lin28/Let-7 loop is seen
as a crucial signaling circuit in oncogenesis.20,21,32,39–41
Particularly, upregulation of Lin28b and altered Let-7 are
associated with advanced disease and reduced patient
survival in ovarian cancer25,31,42,43 and a Lin28b polymorphism has been linked to susceptibility to epithelial ovarian
cancer.32 Our findings show that PSP94 and prostasin
regulate Lin28b and Let-7 expression in ovarian cancer cells
and their expression appear to be strongly correlated in
ovarian cancer patients (Figure 4). Our data suggest that
alteration of Lin28b and Let-7 expression in ovarian cancer
may partially result from overexpression of PSP94 and
prostasin. It is widely accepted that Lin28b overexpression
contributes to tumorigenesis by repressing tumor suppressor
Let-7 expression in ovarian and other cancers,20,21,32,39–41
which is consistent with our view that the PSP94/prostasin
pathway may play a key role in the development of several
cancer types (Figure 5). Our current findings suggest a
potential link between Lin28b/Let-7 signaling and the PSP94/
prostasin pathway in oncogenesis in general. The Lin28/Let-7
pathway is also believed to play a critical role in stem cell
development.18,22,23 Thus, our new findings point to a
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Figure 4 Correlation between PSP94/prostasin signaling and the Lin28b/Let-7 loop in ovarian cancer. (a) PSP94 expression shows positive correlation with Lin28b
expression in ovarian cancer patients. The prediction line is shown: r ¼ 0.33, n ¼ 25. (b) PSP94 expression shows an inverse correlation with Let-7a expression in ovarian
cancer patients. The prediction line is shown: r ¼ 0.26, n ¼ 25. (c) Prostasin expression shows positive correlation with Lin28b expression in ovarian cancer patients. The
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shown: r ¼ 0.27, n ¼ 25
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Real-time reverse transcription quantitative PCR. Real-time quantitative PCR on an ABI PRISM 7900 or 7500 instrument (PE Applied Biosystems)
was performed according to the manufacturer’s instructions and as previously
described.29 PCR cycling conditions were set at 501C for 2 min; 951C for 10 min;
40 cycles for the melting (951C for 15 s) and annealing/extension (601C for 1 min)
steps. qPCR reactions for each template were carried out in triplicate on 96-well
plates. Comparative Ct (PE Applied Biosystems) determined relative expression in
each sample using 18S rRNA as endogenous control.

Figure 5 Proposed model of a PSP94/prostasin-regulated signaling network in
oncogenesis and chemoresistance. The PSP94-prostasin axis may play key roles in
oncogenesis in general. Signaling of PSP94/prostasin and Lin28b/Let-7 plays
critical roles in ovarian cancer development and chemoresistance. Signaling of
PSP94/prostasin and downstream subpathways of the CASP/PAK2-p34, JNK/
c-Jun and MLCK/actin plays important roles in chemoresistance in ovarian cancer

connection between PSP94/prostasin signaling and the
Lin28b/Let-7 loop in oncogenesis and possibly stem cell
development.
In summary, our findings show that PSP94 is an upstream
signaling mediator of prostasin; PSP94 or PSP94/prostasin
signaling is activated and induced in ovarian cancer, and is
connected to the Lin28/Let-7 pathway.
Materials and Methods
Human samples and ethics statement. Frozen GOG (Gynecologic
Oncology Group) samples (54 tumors and 35 normal ovarian tissues including 13
pairs of matched samples) from patients with advanced ovarian cancer were
obtained from the Cooperative Human Tissue Network (CHTN), Pediatric Division,
Children’s Hospital, Columbus, Ohio, USA. Additional 25 frozen ovarian tumor
tissues and plasma samples (19 ovarian cancer and 28 normal controls) were
obtained from Heilongjiang Nongken Hospital (Haerbin, Heilongjiang, China). The
tumor specimens were collected at primary surgery, freshly frozen in liquid
nitrogen and stored at  801C until RNA/DNA extraction. Plasma samples were
first stored at  201C and then transferred to  801C before analysis. Samples
had been stripped off all patient identifiers before shipping to ensure that the
presented molecular laboratory data cannot be linked with any patient. All samples
were evaluated by pathologists.
Cell lines and cell culture. All cell lines were propagated as an adherent
monolayer at 371C in a humidified atmosphere of 5% CO2 supplemented with 10%
heat-inactivated FBS, 100 mg/ml penicillin and 100 mg/ml streptomycin. The HOSE
cell line HIO-80 was maintained in a 1 : 1 mixture of medium M199 and MCDB-105
(Invitrogen, Life Technologies, Inc., Carlsbad, CA, USA). All other cell lines were
maintained in MEM (Invitrogen). Normal ovarian HIO-80 cells were provided by
Dr. Andrew Godwin at the University of Kansas. Ovarian cancer 2008 cells were
provided by Dr. Aikou Okamoto (Jikei University, Japan); Ovca432 was provided
by Dr. Liu T from Chinese Academy of Sciences; Ovca433, Ovcar3 and Caov3
were purchased from ATCC; Ovca432-RP, O432-RP-pro-O, O432-RP-PSP-O and
O432-RP-C were previously generated in our laboratory.29,30
RNA extraction and cDNA generation. Total RNA from GOG samples
was purified by hot phenol/chloroform extraction as previously reported.44
Through reverse transcription, using the Super Script Preamplification System (Life
Technologies, Inc.), cDNA was generated with oligo-dT primers from 5 mg of total
RNA per sample (Life Technologies, Inc.). Total RNA of rest tumor tissues was
prepared with TRIzol reagents (Life Technologies, Inc.). cDNA was synthesized
using Taqman Reverse Transcription (PE Applied Biosystems, Foster City, CA,
USA) from 1 mg of total RNA. cDNAs were used for gene expression profiling.
Cell Death and Disease

Western blot. As previously described,29 cells were rinsed twice with PBS and
solubilized in lysis buffer (150 mM sodium chloride; 50 mM Tris hydrochloride, pH
7.5; 1% glycerol; 1% Nonidet P-40 substitute solution (Sigma-Aldrich, Inc.,
St. Louis, MO, USA)). Equal amounts of total protein were loaded and separated
by SDS-PAGE. Proteins were transferred to a polyvinylidenedifluoride membrane,
which was blocked in 5% skimmed milk, and probed with specific (primary)
antibody, followed by treatment with secondary antibody conjugated to
horseradish peroxidase (1 : 5000). Proteins were visualized by (enhanced)
chemiluminescence detection (Pierce Biotechnology) and exposure to X-ray film.
Beta-actin or GAPDH proteins were visualized by normal chemiluminescence
detection (Pierce Biotechnology) and exposed to less-sensitive X-ray film, which
may result in a relatively weaker signal. All antibodies used in this study were
obtained from Abnova (Taipei, Taiwan, China) or Abcam (Cambridge, MA, USA).
siRNA and cDNA transfection. Cells were transfected with prostasin or
PSP94 cDNA containing vectors using Lipofectamine 2000 (Invitrogen) according
the manufacturer’s instructions.29,30 The parental pCI-neo vector served as a
negative control and stably expressing cells were obtained by Geneticin (Life
Technologies, Inc.) selection. For siRNA experiments, mock transfections and
non-targeting siRNA were used as negative controls. All siRNA experiments used
two alternative siRNAs targeting the same gene to ensure knockdown, and all
experiments were repeated at least three times. Cells were treated for 72 h to allow
for maximum knockdown, and then lysed for immunoblot analysis, RNA preparation
or other assays. siRNA oligos were purchased from Ambion (Austin, TX, USA).
miRNA isolation and quantification. Total RNA was isolated by TRIzol
extraction (Invitrogen). Two micrograms of total RNA were reverse-transcribed into
cDNA using the QuantiMir RT Kit (System Biosciences, Mountain View, CA, USA)
to convert all small RNAs simultaneously into detectable cDNAs for real-time PCR.
miRNA levels were quantified with an ABI PRISM 7900 instrument (PE Applied
Biosystems) and U6 served as an internal control.
Cell survival assay. Cell survival was evaluated as previously described.29
Cells were counted and plated into culture dishes at B10–20% confluence on the
day before treatment. Paclitaxel or PBS as control was added for 20 h and then
removed. Cells were recovered and continuously propagated in normal medium
for 10 days. To quantify final cell numbers, cells were stained with 0.25% crystal
violet/20% ethanol and counted; or the proliferation rate was measured using a
Cell Proliferation Assay kit (Promega, Madison, WI, USA) according to the
manufacturer’s instruction. Briefly, MTS/PMS solution (at a final concentration of
333 mg/ml MTS and 25 mM PMS) was added to each well, and cells were
incubated for 2–3 h at 371C. The absorbance was determined at 490 nm using a
96-well plate ELISA reader. Culture medium was used as a background control.
The experiments were repeated at least three times.
ELISA and PSP94 measurements. The plasma PSP94 concentration
was determined using a PSP94 ELISA Kit (Sanbo Inc., Beijing, China); 100 ml of
standard or plasma samples were loaded to 96-well plates and incubated for 1 h at
371C with 50 ml of HRP conjugate. After rinsing, 50 ml of substrate A and 50 ml of
substrate B were added to each well and incubated for 15 min at 371C; 50 ml of
Stop Solution (Sanbo Inc, Beijing, China) was added before the absorbance at
450 nm was determined with a 96-well plate ELISA reader.
Statistical analysis. The Student’s t-test and correlation analysis for
Windows were used for statistical analysis with significance defined as
Po0.05. All statistical tests and corresponding P-values were two-sided.
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